Overview

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Phase:
PHASE3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
retatrutide